Get the Stockscreener App
13.02
5.22%
-0.6493
Biohaven Ltd stock is traded at $13.02, with a volume of 1.20M.
It is down -5.22% in the last 24 hours and down -5.29% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$13.67
Open:
$13.43
24h Volume:
1.20M
Relative Volume:
0.41
Market Cap:
$1.97B
Revenue:
-
Net Income/Loss:
$-647.68M
P/E Ratio:
-2.2964
EPS:
-5.67
Net Cash Flow:
$-594.49M
1W Performance:
-6.72%
1M Performance:
-5.29%
6M Performance:
+54.42%
1Y Performance:
-5.71%
1-Day Range:
$12.76
$13.63
1-Week Range:
$12.76
$14.97
52-Week Range:
$7.48
$18.57
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
13.01 | 2.06B | 0 | -647.68M | -594.49M | -5.67 |
VRTX
Vertex Pharmaceuticals Inc
|
522.66 | 130.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
795.52 | 82.55B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
185.15 | 72.70B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
951.03 | 59.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
193.56 | 40.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Yale, Biohaven Seek $23M Atty Fee After Trade Secrets Win - Law360
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 49.55% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Biohaven (BHVN) Gains Attention As Pipeline Hopes Meet A Big Fair Value Gap - simplywall.st
BHVN Stock On Track For Best Day In Over 2 Months After SK Biopharmaceuticals Licenses Epilepsy Drug: Retail Now Awaits Obesity Trial Readout - Stocktwits
Biohaven's Kv7 Program Remains Key Stock Driver, UBS Says - finance.yahoo.com
Biohaven (BHVN) discloses options tied to SVP's son - Stock Titan
Biohaven (BHVN) 10K Form and Latest SEC Filings 2026 - MarketBeat
Biohaven Advanced BHV-7000 to Pivotal Trials Without Answering a Question the FDA Requires Every Sponsor to Answer - The Clinical Trial Vanguard
Biohaven (BHVN) Could Be 82% Undervalued Following FDA Hold On Opakalim Trials - simplywall.st
Biohaven Faces New Securities Investigation - stl.news
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
Why Is Biohaven (NYSE:BHVN) Opakalim Under FDA Hold on NYSE Composite? - Kalkine Media
What Does Biohaven (BHVN) FDA Hold Mean For Its Opakalim Program? - simplywall.st
Biohaven’s epilepsy drug hit with FDA clinical hold - Yahoo Finance
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold By Investing.com - Investing.com South Africa
BHVN Stock Builds Momentum Ahead Of Multiple H2 2026 Clinical Data Readouts - Stocktwits
Biohaven’s Newly Out-Licensed Epilepsy Drug Put On A Partial Clinical Hold - insights.citeline.com
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Why is Biohaven Pharmaceutical stock sliding today? - investing.com
Biohaven Shares Plunge as FDA Halts New Enrollment in Epilepsy Drug Trials - finance.biggo.com
BHVN Reiterated by HC Wainwright & Co. -- Price Target Maintained at $10 - GuruFocus
FDA pauses enrollment in Biohaven’s opakalim trials; pivotal readout remains on track - AllSci
Baird reiterates Biohaven stock rating after regulatory update By Investing.com - Investing.com Nigeria
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Baird reiterates Biohaven stock rating after regulatory update - Investing.com
US FDA pauses new enrollment in Biohaven's epilepsy drug trials - Reuters
Why Is Biohaven Stock Tumbling Today?Biohaven (NYSE:BHVN) - Benzinga
FDA Places Partial Clinical Hold on Biohaven’s BHV-7000 Epilepsy Enrollment - Minichart
Biohaven Shares Fall 17% After FDA Places Partial Hold on BHV-7000 Trials - Yahoo Finance
BHVN Stock Crashes 10% – Why Did FDA Put Biohaven’s Epilepsy Trial On Partial Hold? - Yahoo Finance
FDA places partial hold on Biohaven’s epilepsy drug - Yahoo Finance
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September By Investing.com - Investing.com Nigeria
Biohaven stock tumbles after pausing trial enrollment By Investing.com - Investing.com South Africa
Biohaven stock tumbles after pausing trial enrollment - Investing.com
Biohaven faces partial FDA hold on BHV-7000 program - TipRanks
Biohaven pauses new enrollment in epilepsy trials after FDA partial clinical hold - Investing.com Canada
Form 8K Biohaven Pharmaceutical Holding Co For: 10 September - Investing.com India
FDA puts partial hold on Biohaven (NYSE: BHVN) epilepsy trial as 600+ patients keep dosing - Stock Titan
Is Biohaven (BHVN) Priced At A Premium After Its 36% Rise? - simplywall.st
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
Biohaven Pharma stock falls after RBC Capital downgrade By Investing.com - Investing.com India
Biohaven Stock Seen Range-Bound as Near-Term Catalysts Fade, RBC Says - marketscreener.com
Biohaven stock downgraded at RBC Capital Markets (BHVN:NYSE) - Seeking Alpha
Biohaven Pharma stock falls after RBC Capital downgrade - investing.com
BHVN Downgraded by RBC Capital -- Price Target Lowered to $19.00 - GuruFocus
RBC Downgrades Biohaven to Sector Perform From Outperform, Cuts Price Target to $19 From $23, Keeps Speculative Risk - marketscreener.com
Biohaven Shares Fall After RBC Downgrades Stock and Cuts Price Target - Yahoo Finance
Why is Biohaven Pharmaceutical stock sliding today? By Investing.com - Investing.com Canada
RBC Capital downgrades Biohaven Pharma stock rating on valuation By Investing.com - Investing.com South Africa
Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile? - simplywall.st
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
2.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):